The SLC16A3 gene encodes monocarboxylate transporter 4 (MCT4), a transmembrane protein responsible for transporting monocarboxylates such as lactate, pyruvate, and ketone bodies across cell membranes. MCT4 plays a critical role in cellular metabolism, particularly in glycolytic cells, where it exports lactate to maintain pH balance and support energy exchange between oxidative and glycolytic tissues. This transporter is highly expressed in tissues reliant on rapid lactate efflux, such as skeletal muscle, astrocytes, and certain cancer cells.
In cancer biology, MCT4 is linked to the Warburg effect, a metabolic adaptation in tumor cells that promotes glycolysis even under aerobic conditions. Overexpression of MCT4 in aggressive tumors correlates with poor prognosis, as it facilitates lactate shuttling to fuel neighboring cancer cells or modulate the tumor microenvironment. SLC16A3/MCT4 is thus studied as a potential therapeutic target or biomarker for cancer progression and metastasis.
Antibodies against SLC16A3/MCT4 are essential tools for detecting its expression and localization in cells or tissues. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate its role in metabolic diseases, hypoxia responses, and oncogenesis. Researchers also utilize these antibodies to explore MCT4's interaction with chaperones like CD147/Basigin, which is required for its membrane trafficking. Validation of antibody specificity, often via knockout controls or siRNA silencing, is crucial due to homology among MCT family members. Commercial SLC16A3 antibodies vary in clonality, epitope recognition, and host species, enabling flexible experimental designs.